PMV Pharmaceuticals (PMVP) News Today → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free PMVP Stock Alerts $2.13 +0.09 (+4.41%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 9:23 AM | marketbeat.comPMV Pharmaceuticals (NASDAQ:PMVP) Coverage Initiated at Craig HallumCraig Hallum initiated coverage on shares of PMV Pharmaceuticals in a report on Monday. They issued a "buy" rating and a $6.00 price target on the stock.May 9, 2024 | globenewswire.comPMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate HighlightsApril 19, 2024 | finance.yahoo.comPMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth PlansApril 18, 2024 | msn.comPMV Pharmaceuticals (PMVP) Price Target Increased by 45.83% to 8.93April 12, 2024 | marketbeat.comJefferies Financial Group Initiates Coverage on PMV Pharmaceuticals (NASDAQ:PMVP)Jefferies Financial Group initiated coverage on shares of PMV Pharmaceuticals in a report on Friday. They issued a "buy" rating and a $5.00 target price for the company.March 27, 2024 | globenewswire.comPMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsMarch 18, 2024 | finance.yahoo.comPMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s CancerMarch 18, 2024 | globenewswire.comPMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's CancerMarch 16, 2024 | finance.yahoo.comPMVP Apr 2024 5.000 callMarch 11, 2024 | marketbeat.comHC Wainwright Research Analysts Lift Earnings Estimates for PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) - Equities research analysts at HC Wainwright lifted their Q1 2024 earnings per share (EPS) estimates for PMV Pharmaceuticals in a note issued to investors on Thursday, March 7th. HC Wainwright analyst R. Burns now anticipates that the companyMarch 7, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for PMV Pharmaceuticals (NASDAQ:PMVP)HC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a report on Thursday.March 6, 2024 | marketbeat.comRTW Investments LP Sells 653,766 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)RTW Investments LP trimmed its stake in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 21.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,375,785 shares of the company's stock after sellingMarch 3, 2024 | marketbeat.comAlkeon Capital Management LLC Acquires 867,547 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)Alkeon Capital Management LLC lifted its position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 58.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,347,414 shares of the company'March 3, 2024 | finanznachrichten.dePMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsMarch 1, 2024 | markets.businessinsider.comOppenheimer Keeps Their Hold Rating on PMV Pharmaceuticals (PMVP)March 1, 2024 | finance.yahoo.comPMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial ResultsMarch 1, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on PMV Pharmaceuticals (PMVP)February 29, 2024 | globenewswire.comPMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsFebruary 26, 2024 | finance.yahoo.comPMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 24, 2024 | marketbeat.comCitigroup Inc. Has $2.25 Million Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)Citigroup Inc. boosted its position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 468.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 365,564 shares of the company's stock after purchasing an additional 301,2January 19, 2024 | finanznachrichten.dePMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayJanuary 18, 2024 | marketwatch.comPMV Phamra to Prioritize PC14586 Clinical Development, Will Cut Staff by 30%January 18, 2024 | msn.comPMV to focus on lead drug, slashes workforce by 30%January 18, 2024 | finance.yahoo.comPMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayJanuary 5, 2024 | msn.comPMV Pharmaceuticals names Michael Carulli as CFOJanuary 5, 2024 | finance.yahoo.comPMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage DevelopmentDecember 28, 2023 | msn.comLadenburg Thalmann starts PMV Pharmaceuticals at buyDecember 28, 2023 | benzinga.comPMV Pharma Stock (NASDAQ:PMVP), Analyst Ratings, Price Targets, PredictionsDecember 27, 2023 | benzinga.comPMV Pharma Stock (NASDAQ:PMVP), Short Interest ReportDecember 27, 2023 | msn.comLadenburg Thalmann Initiates Coverage of PMV Pharmaceuticals (PMVP) with Buy RecommendationDecember 27, 2023 | msn.com2 Red-Hot Stocks Highlight Wednesday's Top Wall Street Upgrades and DowngradesDecember 27, 2023 | finance.yahoo.comGracell downgrade, Fusion upgrade: Wall Street's top analyst callsDecember 27, 2023 | marketbeat.comLADENBURG THALM/SH SH Initiates Coverage on PMV Pharmaceuticals (NASDAQ:PMVP)LADENBURG THALM/SH SH assumed coverage on shares of PMV Pharmaceuticals in a report on Wednesday. They set a "buy" rating and a $7.00 price objective on the stock.November 14, 2023 | seekingalpha.comPMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower PriceNovember 10, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Century Therapeutics (IPSC), Phathom Pharmaceuticals (PHAT)November 9, 2023 | finanznachrichten.dePMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate HighlightsNovember 9, 2023 | finance.yahoo.comPMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate HighlightsNovember 9, 2023 | finance.yahoo.comPMV Pharmaceuticals Inc (PMVP) Reports Q3 2023 Financial Results and Corporate UpdatesOctober 16, 2023 | markets.businessinsider.comPMV Pharmaceuticals Receives ‘Buy’ Rating Based on PYNNACLE Trial Results and Ongoing Cancer Research ProgressOctober 16, 2023 | finance.yahoo.comPMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerOctober 12, 2023 | msn.comPrecision Oncology PMV Pharmaceuticals Reveals Early Data From Cancer Study In Pretreated PatientsOctober 12, 2023 | finance.yahoo.comPMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C MutationOctober 12, 2023 | marketbeat.comTrading was temporarily halted for "PMVP" at 12:10 PM with a stated reason of "LULD pause."October 11, 2023 | finance.yahoo.comPMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL WebinarOctober 6, 2023 | finance.yahoo.comWall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High?September 29, 2023 | marketbeat.com30,500 Shares in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Acquired by Denali Advisors LLCDenali Advisors LLC purchased a new position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 30,500 shares of the company's stock, valued at aSeptember 20, 2023 | finance.yahoo.comPMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 3, 2023 | marketbeat.comPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Purchased by Principal Financial Group Inc.Principal Financial Group Inc. increased its position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 2.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 917,885 shares of the company'sAugust 30, 2023 | finance.yahoo.comWall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a BetAugust 29, 2023 | finance.yahoo.comPMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden Cross Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk’s Next Move Will Disrupt AI Forever (Ad)A revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100. Get all the information here. PMVP Media Mentions By Week PMVP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PMVP News Sentiment▼1.300.58▲Average Medical News Sentiment PMVP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PMVP Articles This Week▼51▲PMVP Articles Average Week Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Relmada Therapeutics News Citius Pharmaceuticals News Rezolute News Allakos News Societal CDMO News OptiNose News Cellectar Biosciences News Cue Biopharma News Assertio News Genelux News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PMVP) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
